Literature DB >> 9767457

Lymphotactin: a key regulator of lymphocyte trafficking during acute graft rejection.

J D Wang1, N Nonomura, S Takahara, B S Li, H Azuma, N Ichimaru, Y Kokado, K Matsumiya, T Miki, S Suzuki, A Okuyama.   

Abstract

The attraction of leucocytes to allografts is essential for rejection. The process is controlled by chemokines. In order to clarify the role of lymphotactin (a cytokine that represents a novel branch of the chemokine superfamily) in regulating leucocyte trafficking during graft rejection, we used rat renal transplantation models to examine its gene expression and the distribution of lymphotactin-expressing cells in renal grafts. Lymphotactin mRNA was upregulated strongly in acutely rejecting renal allografts. The mRNA was undetectable in isografts, chronically rejecting renal allografts or normal kidney. Once lymphotactin was expressed, large numbers of infiltrating lymphocytes were seen. Moreover extended studies demonstrated that in cultured rat spleen cells the expression of lymphotactin mRNA was markedly induced by phytohaemagglutinin (PHA) or phorbol myristate acetate (PMA), and such induction was inhibited by the immunosuppressive drugs FK506 and cyclosporin. Collectively, these observations provide new evidence demonstrating that lymphotactin is a key regulator of lymphocyte motility and adhesiveness during acute allograft rejection. FK506 and cyclosporin inhibition of lymphotactin expression is likely to represent an important molecular mechanism of the action of the drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9767457      PMCID: PMC1364376          DOI: 10.1046/j.1365-2567.1998.00570.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  21 in total

Review 1.  Chemokines, leukocyte trafficking, and inflammation.

Authors:  T J Schall; K B Bacon
Journal:  Curr Opin Immunol       Date:  1994-12       Impact factor: 7.486

2.  Chemokines as mediators of allergic inflammation.

Authors:  K B Bacon; T J Schall
Journal:  Int Arch Allergy Immunol       Date:  1996-02       Impact factor: 2.749

Review 3.  New immunosuppressive treatment in transplantation medicine.

Authors:  G H Haydon; P C Hayes
Journal:  Baillieres Clin Gastroenterol       Date:  1994-09

4.  Infiltration patterns of macrophages and lymphocytes in chronically rejecting rat kidney allografts.

Authors:  U W Heemann; S G Tullius; T Tamatami; M Miyasaka; E Milford; N L Tilney
Journal:  Transpl Int       Date:  1994-08       Impact factor: 3.782

5.  Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts.

Authors:  H Azuma; J Binder; U Heemann; C Schmid; S G Tullius; N L Tilney
Journal:  Transplantation       Date:  1995-02-27       Impact factor: 4.939

6.  The correlation of intragraft cytokine expression with rejection in rat small intestine transplantation.

Authors:  S V McDiarmid; D G Farmer; J S Kuniyoshi; M Robert; A Khadavi; A Shaked; R W Busuttil
Journal:  Transplantation       Date:  1994-09-27       Impact factor: 4.939

7.  Molecular cloning and functional characterization of human lymphotactin.

Authors:  J Kennedy; G S Kelner; S Kleyensteuber; T J Schall; M C Weiss; H Yssel; P V Schneider; B G Cocks; K B Bacon; A Zlotnik
Journal:  J Immunol       Date:  1995-07-01       Impact factor: 5.422

8.  Acute rejection episodes--best predictor of long-term primary cadaveric renal transplant survival.

Authors:  R Ferguson
Journal:  Clin Transplant       Date:  1994-06       Impact factor: 2.863

9.  Sequential cytokine dynamics in chronic rejection of rat renal allografts: roles for cytokines RANTES and MCP-1.

Authors:  K C Nadeau; H Azuma; N L Tilney
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

10.  Chemokines regulate cellular polarization and adhesion receptor redistribution during lymphocyte interaction with endothelium and extracellular matrix. Involvement of cAMP signaling pathway.

Authors:  M A del Pozo; P Sánchez-Mateos; M Nieto; F Sánchez-Madrid
Journal:  J Cell Biol       Date:  1995-10       Impact factor: 10.539

View more
  9 in total

1.  Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection.

Authors:  W Gao; P S Topham; J A King; S T Smiley; V Csizmadia; B Lu; C J Gerard; W W Hancock
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

2.  IFN-gamma, produced by NK cells that infiltrate liver allografts early after transplantation, links the innate and adaptive immune responses.

Authors:  Hideaki Obara; Kazuhito Nagasaki; Christine L Hsieh; Yasuhiro Ogura; Carlos O Esquivel; Olivia M Martinez; Sheri M Krams
Journal:  Am J Transplant       Date:  2005-09       Impact factor: 8.086

3.  Structural rearrangement of human lymphotactin, a C chemokine, under physiological solution conditions.

Authors:  E Sonay Kuloğlu; Darrell R McCaslin; John L Markley; Brian F Volkman
Journal:  J Biol Chem       Date:  2002-03-11       Impact factor: 5.157

4.  Expression of the T-cell chemoattractant chemokine lymphotactin in Crohn's disease.

Authors:  P Middel; P Thelen; S Blaschke; F Polzien; K Reich; V Blaschke; A Wrede; K M Hummel; B Gunawan; H J Radzun
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

5.  Chemokine expression dynamics in mycobacterial (type-1) and schistosomal (type-2) antigen-elicited pulmonary granuloma formation.

Authors:  B Qiu; K A Frait; F Reich; E Komuniecki; S W Chensue
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

6.  Chapter 3. Lymphotactin structural dynamics.

Authors:  Brian F Volkman; Tina Y Liu; Francis C Peterson
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

Review 7.  Chemokines in chronic liver allograft dysfunction pathogenesis and potential therapeutic targets.

Authors:  Bin Liu; Jing Li; Lu-Nan Yan
Journal:  Clin Dev Immunol       Date:  2013-12-08

Review 8.  Neutralizing endogenous chemokines with small molecules. Principles and potential therapeutic applications.

Authors:  Jean-Luc Galzi; Muriel Hachet-Haas; Dominique Bonnet; Francois Daubeuf; Sandra Lecat; Marcel Hibert; Jacques Haiech; Nelly Frossard
Journal:  Pharmacol Ther       Date:  2010-02-01       Impact factor: 12.310

9.  Blockade of XCL1/Lymphotactin Ameliorates Severity of Periprosthetic Osteolysis Triggered by Polyethylene-Particles.

Authors:  Yuan Tian; Mohamad Alaa Terkawi; Tomohiro Onodera; Hend Alhasan; Gen Matsumae; Daisuke Takahashi; Masanari Hamasaki; Taku Ebata; Mahmoud Khamis Aly; Hiroaki Kida; Tomohiro Shimizu; Keita Uetsuki; Ken Kadoya; Norimasa Iwasaki
Journal:  Front Immunol       Date:  2020-08-04       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.